Reaction
Occipital Neuralgia reporting signals
As of the last recalculation, Occipital Neuralgia appears in 555 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is INDOMETHACIN (PRR 40.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Indomethacin | 14 | 40.6 | 40.7 |
| Ketoprofen | 13 | 38.0 | 38.1 |
| Rizatriptan Benzoate | 7 | 26.1 | 26.1 |
| Ropinirole | 10 | 24.9 | 24.9 |
| Fremanezumab-Vfrm | 7 | 23.1 | 23.2 |
| Botulinum Toxin Type A | 7 | 21.4 | 21.4 |
| Galcanezumab-Gnlm | 17 | 20.9 | 20.9 |
| Eptinezumab-Jjmr | 5 | 20.8 | 20.8 |
| Cenobamate | 4 | 18.1 | 18.1 |
| Calcium, Magnesium, Potassium, And Sodium Oxybates | 4 | 17.5 | 17.5 |
| Rimegepant Sulfate | 5 | 14.9 | 14.9 |
| Pseudoephedrine Hydrochloride | 4 | 14.7 | 14.7 |
| Onabotulinumtoxina | 28 | 14.3 | 14.3 |
| Pseudoephedrine Hcl | 4 | 13.7 | 13.7 |
| Lurasidone Hydrochloride | 7 | 12.7 | 12.7 |
| Erenumab-Aooe | 18 | 12.6 | 12.6 |